Saverio D’Amico
A5010365030- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- AI in cancer detection
- Radiomics and Machine Learning in Medical Imaging
- Chronic Myeloid Leukemia Treatments
- Digital Imaging for Blood Diseases
- Artificial Intelligence in Healthcare and Education
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Acute Lymphoblastic Leukemia research
- Biochemical and Molecular Research
- Breast Cancer Treatment Studies
- Cancer-related molecular mechanisms research
- Retinoids in leukemia and cellular processes
- Biosimilars and Bioanalytical Methods
- Privacy-Preserving Technologies in Data
- Monoclonal and Polyclonal Antibodies Research
- Bone and Joint Diseases
- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- Delphi Technique in Research
- Knee injuries and reconstruction techniques
- Mobile Health and mHealth Applications
IRCCS Humanitas Research Hospital
2022-2025
Humanitas University
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
1988-2025
University of Pavia
1988-2025
TRAIN Consortium
2024-2025
Leukemia and Lymphoma Society
2022
Ministero della Salute
2022
Institute of Biomedical Science
2022
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve prediction of clinical outcome currently available tool (Revised [IPSS-R]). We aimed provide an extensive validation IPSS-M.
Synthetic data are artificial generated without including any real patient information by an algorithm trained to learn the characteristics of a source set and became widely used accelerate research in life sciences. We aimed (1) apply generative intelligence build synthetic different hematologic neoplasms; (2) develop validation framework assess fidelity privacy preservability; (3) test capability clinical/translational hematology.
Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating benefits and risks of HSCT MDS, timing being a crucial question. Here, we aimed to develop validate decision support system define optimal MDS on basis clinical genomic information as provided by Molecular International Prognostic Scoring System (IPSS-M).
Rare cancers constitute over 20% of human neoplasms, often affecting patients with unmet medical needs. The development effective classification and prognostication systems is crucial to improve the decision-making process drive innovative treatment strategies. We have created implemented MOSAIC, an artificial intelligence (AI)-based framework designed for multimodal analysis, classification, personalized prognostic assessment in rare cancers. Clinical validation was performed on...
Background Sex is a major source of diversity among patients and sex-informed approach becoming new paradigm in precision medicine.We aimed to describe sex myelodysplastic syndromes terms disease genotype, phenotype, clinical outcome.Moreover, we sought incorporate information into the decision-making process as fundamental component patient individuality. MethodsIn this multicentre, observational cohort study, retrospectively analysed 13 284 aged 18 years or older with diagnosis syndrome...
Several computational pipelines for biomedical data have been proposed to stratify patients and predict their prognosis through survival analysis. However, these analyses are usually performed independently, without integrating the information derived from each of them. Clustering is an underexplored problem, current approaches limited applications, whose heterogeneous multimodal, with poor scalability high-dimensionality. We introduce VAE-Surv, a multimodal framework patients'...
ABSTRACT Due to the lack of effective therapeutic approach, glioblastoma (GBM) remains one most malignant brain tumour. By in vitro investigations on primary GBM stem cells, we highlighted underlying mechanisms drug resistance alkylating agents, DNA damage responses. Here, flow cytometric analysis and viability repopulation assays were used assess long‐term cytotoxic effect induced by administration a fourth‐generation platinum prodrug, ( OC...
PURPOSE Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) investigate their clinical effect. PATIENTS AND METHODS analyzed cohort 6,204 patients with MDS subsets available information on RNA sequencing cells (n = 109), high-dimensional phenotype immune 77), multiomics analysis (RNA proteomics) single 15). An independent validation was performed...
Decision about the optimal timing of a treatment procedure in patients with hematologic neoplasms is critical, especially for cellular therapies (most including allogeneic hematopoietic stem-cell transplantation [HSCT]). In absence evidence from randomized trials, real-world observational data become beneficial to study effect timing. this study, framework estimate expected outcome after an intervention time-to-event scenario developed, aim optimizing personalized manner.
RSClin is a proprietary algorithm that integrates clinical-pathological (CP) factors and genomic risk in patients with N0 HR+/HER2- eBC. refines the prognosis of distant recurrence (DR) chemotherapy (CT) benefit more accurately than CP Recurrence Score (RS) alone. Since not available Europe, we aimed to validate an automated ML-based nomogram able predict outcomes potential clinical impact European countries. We retrospectively collected characteristics 290 eBC from 3 hospitals Italy Belgium...